Timolol. Hypotensive effect, used alone and in combination for treatment of increased intraocular pressure.
In 43 persons with increased intraocular pressure (IOP) Timolol maleate eye drops (0.25% and 0.5%) were used as a single and combined treatment. A significant decrease in IOP was noticed in 34 persons (P less than 0.001) initially. No diminished effect of treatment was apparent after 9 weeks in 34 subjects or after 15 weeks in 23 subjects with Timolol alone. In nine persons with high IOP, Timolol had a significant (P less than 0.001) but insufficient lowering effect. Epinephrine (1%) and acetazolamide appeared to have an additive effect in these cases. No serious local or systemic adverse effects were discovered.
D000086:Acetazolamide / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010862:Pilocarpine / Q000627:therapeutic use; D011412:Propanolamines / Q000008:administration & dosage*; D013999:Timolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D010862:Pilocarpine; D013999:Timolol; D000086:Acetazolamide; D004837:Epinephrine